We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Eli Lilly’s Potential Blockbuster in Type 2 Diabetes
FDA Approves Eli Lilly’s Potential Blockbuster in Type 2 Diabetes
The FDA has approved Eli Lilly’s Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval marks the first new class of drugs for type 2 diabetes in 10 years.